|
1
|
Niederau C, Crass RA, Silver G, Ferrell LD
and Grendell JH: Therapeutic regimens in acute experimental
hemorrhagic pancreatitis. Effects of hydration, oxygenation,
peritoneal lavage, and a potent protease inhibitor.
Gastroenterology. Gastroenterology. 95:1648–1657. 1988.PubMed/NCBI
|
|
2
|
Wilson C and Imrie CW: Effective
intraperitoneal antiprotease therapy for taurocholate-induced
pancreatitis in rats. Br J Surg. 77:1252–1255. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fric P, Slabý J, Kasafírek E, Kocna P and
Marek J: Effective peritoneal therapy of acute pancreatitis in the
rat with glutaryl-trialanin-ethylamide: a novel inhibitor of
pancreatic elastase. Gut. 33:701–706. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leonhardt U, Seidensticker F, Fussek M,
Stöckmann F and Creutzfeldt W: Camostate (FOY-305) improves the
therapeutic effect of peritoneal lavage on taurocholate induced
pancreatitis. Gut. 31:934–937. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohnishi H, Kosuzume H, Ashida Y, Kato K
and Honjo I: Effects of urinary trypsin inhibitor on pancreatic
enzymes and experimental acute pancreatitis. Dig Dis Sci. 29:26–32.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tani S, Otsuki M, Itoh H, et al: The
protective effect of the trypsin inhibitor urinastatin on
cerulein-induced acute pancreatitis in rats. Pancreas. 3:471–476.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Inoue K, Takano H, Shimada A, et al:
Urinary trypsin inhibitor protects against systemic inflammation
induced by lipopolysaccharide. Mol Pharmacol. 67:673–680. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li F, Zhang H, Xu KY, Wei Q and Zhou GX:
Role of the chemokine fractalkine in a rat model of acute
necrotizing pancreatitis and the interventional effect of
ulinastatin. Arch Iran Med. 16:83–87. 2013.PubMed/NCBI
|
|
9
|
Inoue K, Takano H, Shimada A, et al:
Urinary trypsin inhibitor protects against systemic inflammation
induced by lipopolysaccharide. Mol Pharmacol. 67:673–680. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li HM, Feng QX, Dou KF, et al: Treatment
of acute pancreatitis with ulinastatin: a report of 72 cases. Xi
Bei Guo Fang Yi Xue Za Zhi. 23:183–185. 2002.[In Chinese].
|
|
11
|
Rongione AJ, Kusske AM, Kwan K, et al:
Interleukin 10 reduces the severity of acute pancreatitis in rats.
Gastroenterology. 112:960–967. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Balldin G, Borgström A, Genell S and
Ohlsson K: The effect of peritoneal lavage and aprotinin in the
treatment of severe acute pancreatitis. Res Exp Med (Berl).
183:203–213. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ohlsson K and Tegner H: Experimental
pancreatitis in the dog. Demonstration of trypsin in ascitic fluid,
lymph and plasma. Scand J Gastroenterol. 8:129–133. 1973.PubMed/NCBI
|
|
14
|
Bhatia M, Wong FL, Cao Y, et al:
Pathophysiology of acute pancreatitis. Pancreatology. 5:132–144.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Berling R, Borgström A and Ohlsson K:
Peritoneal lavage with aprotinin in patients with severe acute
pancreatitis. Effects on plasma and peritoneal levels of trypsin
and leukocyte proteases and their major inhibitors. Int J
Pancreatol. Int J Pancreatol. 24:9–17. 1998.
|
|
16
|
Dong Z, Petrov MS, Xu J, et al: Peritoneal
lavage for severe acute pancreatitis: a systematic review of
randomised trials. World J Surg. 34:2103–2108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hirano T and Manabe T: Human urinary
trypsin inhibitor, urinastatin, prevents pancreatic injuries
induced by pancreaticobiliary duct obstruction with cerulein
stimulation and systemic hypotension in the rat. Arch Surg. Arch
Surg. 128:1322–1329. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang G, Wen J, Wilbur RR, et al: The
effect of somatostatin, ulinastatin and Salvia miltiorrhiza on
severe acute pancreatitis treatment. Am J Med Sci. 346:371–376.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wallner G, Solecki M, Ziemiakowicz R, et
al: Morphological changes of the pancreas in course of acute
pancreatitis during treatment with Ulinastatin. Pol Przegl Chir.
85:114–122. 2013.PubMed/NCBI
|
|
20
|
Keck T, Balcom JH, Antoniu BA, et al:
Regional effects of nafamostat, a novel potent protease and
complement inhibitor, on severe necrotizing pancreatitis. Surgery.
130:175–181. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Watanabe S: Acute pancreatitis: overview
of medical aspects. Pancreas. 16:307–311. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Matsukawa H, Hara A, Ito T, et al:
Continuous arterial infusion of protease inhibitor with
supplementary therapy for the patients with severe acute
pancreatitis - clinical effect of arterial injection of
ulinastatin. Nihon Shokakibyo Gakkai Zasshi. Nihon Shokakibyo
Gakkai Zasshi. 95:1229–1234. 1998.[In Japanese]. PubMed/NCBI
|
|
23
|
Botoi G and Andercou A: Early and
prolonged peritoneal lavage with laparoscopy in severe acute
pancreatitis. Chirurgia (Bucur). 104:49–53. 2009.[In Romanian].
PubMed/NCBI
|
